1. Home
  2. ZBRA vs IONS Comparison

ZBRA vs IONS Comparison

Compare ZBRA & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zebra Technologies Corporation

ZBRA

Zebra Technologies Corporation

HOLD

Current Price

$365.87

Market Cap

12.6B

Sector

Industrials

ML Signal

HOLD

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$54.09

Market Cap

12.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZBRA
IONS
Founded
1969
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6B
12.1B
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
ZBRA
IONS
Price
$365.87
$54.09
Analyst Decision
Buy
Strong Buy
Analyst Count
8
22
Target Price
$321.88
$93.36
AVG Volume (30 Days)
810.8K
4.4M
Earning Date
05-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.71
EPS
7.54
N/A
Revenue
$5,396,000,000.00
N/A
Revenue This Year
$13.27
N/A
Revenue Next Year
$5.43
$77.99
P/E Ratio
$48.94
N/A
Revenue Growth
8.33
N/A
52 Week Low
$199.05
$40.37
52 Week High
$376.70
$86.74

Technical Indicators

Market Signals
Indicator
ZBRA
IONS
Relative Strength Index (RSI) 80.56 37.62
Support Level $237.04 $50.01
Resistance Level N/A $57.48
Average True Range (ATR) 12.73 2.03
MACD 10.53 0.66
Stochastic Oscillator 90.77 68.16

Price Performance

Historical Comparison
ZBRA
IONS

About ZBRA Zebra Technologies Corporation

Zebra Technologies is the largest provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Share on Social Networks: